[{"id":"3d25c448-acf8-4e6b-a932-342422e06f4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06908304","created_at":"2025-09-07T01:12:54.209Z","updated_at":"2025-09-07T01:12:54.209Z","phase":"Phase 3","brief_title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","source_id_and_acronym":"NCT06908304","lead_sponsor":"Maia Biotechnology","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 07/29/2026","primary_completion_date":" 07/29/2026","study_txt":" Completion: 07/29/2027","study_completion_date":" 07/29/2027","last_update_posted":"2025-04-08"},{"id":"0388c28a-65ca-445b-9f8d-078ae068c2a4","acronym":"THIO-101","url":"https://clinicaltrials.gov/study/NCT05208944","created_at":"2025-02-26T12:39:23.695Z","updated_at":"2025-02-26T12:39:23.695Z","phase":"Phase 2","brief_title":"THIO Sequenced with Cemiplimab in Advanced NSCLC","source_id_and_acronym":"NCT05208944 - THIO-101","lead_sponsor":"Maia Biotechnology","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • ateganosine (THIO)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 06/08/2022","start_date":" 06/08/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-11-22"}]